Results 211 to 220 of about 297,289 (305)
A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients? [PDF]
Muñoz Ayala K +2 more
europepmc +1 more source
ABSTRACT This study aimed to evaluate the hemodynamic significance of in‐stent restenosis (ISR) by using a combined anatomical‐functional approach with photon‐counting CT coronary angiography (APEX‐CT CTA) and dynamic CT myocardial perfusion imaging (CT‐MPI). We prospectively enrolled 239 symptomatic patients at least 9 months after PCI.
Liang‐Shi Wang +6 more
wiley +1 more source
LDL cholesterol and clinical outcomes in heart failure with reduced ejection fraction a competing risk analysis. [PDF]
Wang Q +7 more
europepmc +1 more source
ABSTRACT Patients with chronic hepatitis C (CHC) frequently present with steatotic liver disease (SLD) and cardiometabolic risk factors (CMRFs). This study aimed to evaluate the impact of SLD and CMRFs on liver‐related outcomes (LROs) in CHC patients after HCV eradication.
Chung‐Feng Huang +15 more
wiley +1 more source
ABSTRACT Hyperglycemia, glucose fluctuations, and thyroid dysfunction contribute to the progression of diabetic nephropathy. This study aimed to investigate the associations of glycemia, glucose variability, and thyroid hormones with albuminuria in patients with type 2 diabetes mellitus (T2DM). In total, 451 T2DM patients were included.
Na Luo +12 more
wiley +1 more source
Editorial: Cardiovascular risk and lipoprotein(a): beyond LDL cholesterol. [PDF]
Mandraffino G, D'Erasmo L.
europepmc +1 more source
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) and obstructive sleep apnea (OSA) are comorbid conditions that synergistically increase cardiovascular risk through systemic inflammation and insulin resistance. While continuous positive airway pressure (CPAP) is the standard treatment for OSA, its efficacy in improving hepatic ...
Hsiao‐Chin Shen +10 more
wiley +1 more source
ABCC4 impairs the clearance of plasma LDL cholesterol through suppressing LDLR expression in the liver. [PDF]
Chen J +18 more
europepmc +1 more source

